Barclays Initiates Coverage On Sutro Biopharma with Overweight Rating, Announces Price Target of $56

Benzinga Newsdesk www.benzinga.com Positive 49.6%

Neg 0% Neu 0% Pos 49.6%

Barclays analyst Lukas Shumway initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Overweight rating and announces Price Target of $56.